Related Experiment Video
Updated: Jul 16, 2026

Induction of Leptomeningeal Cells Modification Via Intracisternal Injection
Published on: May 7, 2020
Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid
Patricia Dickson1, Michael McEntee, Carole Vogler
1Division of Medical Genetics, Department of Pediatrics, LA Biomed at Harbor-UCLA, Torrance, CA 90502, USA. pdickson@ucla.edu
Abstract:
Treatment of brain disease with recombinant proteins is difficult due to the blood-brain barrier. As an alternative to direct injections into the brain, we studied whether application of high concentrations of therapeutic enzymes via intrathecal (IT) injections could successfully drive uptake across the ependyma to treat brain disease. We studied IT enzyme replacement therapy with recombinant human iduronidase (rhIDU) in canine mucopolysaccharidosis I (MPS I, Hurler syndrome), a lysosomal storage disorder with brain and meningeal involvement. Monthly or quarterly IT treatment regimens with rhIDU achieved supranormal iduronidase enzyme levels in the brain, spinal cord, and spinal meninges. All regimens normalized total brain glycosaminoglycan (GAG) storage and reduced spinal meningeal GAG storage by 58-70%. The improvement in GAG storage levels persisted three months after the final IT dose. The successful use of enzyme therapy via the CSF represents a potentially useful approach for lysosomal storage disorders.
Related Concept Videos
Drug Delivery: Parenteral Route
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
Cerebral Edema ll: Pathophysiology
Cerebral Edema l: Introduction
Cerebrospinal Fluid
CSF Production
CSF is produced mainly in the choroid plexus, a network of capillaries and ependymal cells located within the ventricular system of the brain.
Cytotoxic Edema: Pathophysiology
The Blood-brain Barrier
